BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tegileridine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tegileridine\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07412223-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Tegileridine: Phase 4 readout est. (NCT07412223)
DESCRIPTION:Tegileridine\, phase 4.\nStudy: Effect of Tegileridine on Posto
 perative Bowel Function Recovery in Abdominal Surgery\nEstimated primary c
 ompletion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tegileridine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07412223
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07924306-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Tegileridine: Phase 4 readout est. (NCT07924306)
DESCRIPTION:Tegileridine\, phase 4.\nStudy: Effects of Biased Opioid Agonis
 ts on Gastrointestinal Recovery After Gynecologic Laparoscopic Surgery\nEs
 timated primary completion: 20 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/tegileridine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07924306
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07386626-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tegileridine: Phase na readout est. (NCT07386626)
DESCRIPTION:Tegileridine\, phase na.\nStudy: Tegileridine Combined With Int
 ercostal Nerve Block After Thoracoscopic Lung Resection\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/tegileridine#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07386626
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637968-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Tegileridine: Phase 4 readout est. (NCT07637968)
DESCRIPTION:Tegileridine\, phase 4.\nStudy: Tegileridine vs Sufentanil for 
 Postoperative Pain Management and Gastrointestinal Recovery After Major La
 paroscopic Abdominal Surgery\nEstimated primary completion: 1 January 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tegileridine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07637968
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07844512-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tegileridine: Phase 3 readout est. (NCT07844512)
DESCRIPTION:Tegileridine\, phase 3.\nStudy: Safety and Analgesic Efficacy o
 f the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative An
 algesia in Patients Undergoing Bariatric Surgery\nEstimated primary comple
 tion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tegileridine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07844512
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229495-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Tegileridine: Phase 4 readout est. (NCT07229495)
DESCRIPTION:Tegileridine\, phase 4.\nStudy: Tegileridine for Postoperative 
 Pain After Adolescent Scoliosis Surgery\nEstimated primary completion: 30 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tegiler
 idine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07229495
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933640-11096@assetmemo.bio
DTSTAMP:20261121T005604Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Tegileridine: Phase na readout est. (NCT07933640)
DESCRIPTION:Tegileridine\, phase na.\nStudy: A Clinical Study on Vagus Nerv
 e Blockade at the Gastroesophageal Junction Combined With Tegileridine in 
 the Very Early Postoperative Recovery Following Bariatric Surgery\nEstimat
 ed primary completion: 15 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tegileridine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07933640
URL:https://assetmemo.bio/drug/tegileridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
